Health-related quality of life in gout: a systematic review

Chandratre, Priyanka; Roddy, Edward; Clarson, Lorna; Richardson, Jane; Hider, Samantha L.; Mallen, Christian

doi:10.1093/rheumatology/ket265

Cited by 123 publications

(92 citation statements)

References 40 publications

(159 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…32 A recent study, however, found that the linking relationships for PROMIS Pain Interference and the Brief Pain Inventory were very similar when derived from general population and multiple sclerosis groups. 36,37 Nevertheless, it will be necessary to replicate our study with samples drawn from populations with a higher density of scores at either end of the physical function continuum.…”

Section: Discussionmentioning

confidence: 99%

Establishing a Common Metric for Physical Function: Linking the HAQ-DI and SF-36 PF Subscale to PROMIS® Physical Function

Schalet

Revicki²,

Cook

et al. 2015

J GEN INTERN MED

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Establishing a Common Metric for Physical Function: Linking the HAQ-DI and SF-36 PF Subscale to PROMIS® Physical Function

Schalet

Revicki²,

Cook

et al. 2015

J GEN INTERN MED

View full text Add to dashboard Cite

“…Severe renal failure Therapeutic options (1) Abbreviations: PPI, proton pump inhibitor; others, see TABLE 1 250 mg twice daily) for up to 6 months is support ed by evidence from RCTs and observational stud ies. 39 Patients and physicians need to be aware, however, that there is a risk of neurotoxicity and myopathy with colchicine prophylaxis in patients with renal impairment and in patients receiving statins, so renal function should be assessed be fore prescribing colchicine or NSAIDs.…”

Section: Eular Recommendations For the Management Of Flares In Patienmentioning

confidence: 99%

“…cyclosporine, cimetidine, clarithromycin, eryth romycin, ketoconazole, and verapamil ), and should be used with caution and at low doses in patients taking drugs which are potent inhibitors of P glyco protein or cytochrome P450 3A4 (CYP3A4) (eg, Treat as early as possible (1) Resolution of flare Avoid colchicine (2) Colchicine (2) (1 mg followed 1 hour later by 0.5 mg) NSAID (2) (classic or coxibs + PPI if appropriate) Prednisolone (2) (30-35 mg/d for 3-5 days)…”

mentioning

confidence: 99%

See 1 more Smart Citation

Current management of gout: practical messages from EULAR 2016 guidelines

Nuki¹,

Doherty²,

Richette³

2017

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

REVIEW ARTICLE Current management of gout: practical messages from 2016 EULAR guidelines 267 where these differ significantly from the earli er guidelines and other recent national and in ternational recommendations for the manage ment of gout.Why do we need updated recommendations? There were at least half a dozen good reasons why the EULAR recommendations needed to be up dated in 2016. 1 Knowledge of the pathophysiology of uric acid (UA) transport, urate crystal inflammation, and the comorbidities associated with gout had ad vanced considerably. 2 New pharmaceutical options had become available and the evidence base for the efficacy and safety of available drugs had expanded in the last decade. 3 The incidence, prevalence, and severity of gout had continued to increase 7 despite the availability Introduction Gout is a chronic crystal deposition disorder in which crystals of monosodium urate can cause chronic arthritis, tophi, urolithiasis and renal disease, as well as recurrent acute arthritis and bursitis. Gouty arthritis and tophi can lead to chronic disability and impairment of health related quality of life, 1 but gout is also frequently associated with comorbidities such as obesity, di abetes mellitus, hypertension, and cardiovascular disease, 2,3 as well as with increased mortality. 3,4 The ABSTRACTThe European League Against Rheumatism published updated recommendations for the management of gout in 2016, comprising 3 overarching principles and 11 key recommendations for clinical practice. Patient education about the pathophysiology of gout and its comorbidities, as well as the existence of effective treatments are important, and understanding the principles of managing acute attacks and eliminating urate crystals by lifelong lowering of the serum urate (SU) below a target level are essential. Advice about lifestyle, diet, weight, and other risk factors, as well as the need to screen for and manage comorbidities are emphasized. For the treatment of flares, colchicine, nonsteroidal anti -inflammatory drugs (NSAIDs), and oral or intraarticular steroids, or a combination thereof, are recommended. In patients with frequent flares and contraindications to colchicine, NSAIDs, and corticosteroids, an interleukin -1 blocker should be considered. Urate -lowering therapy (ULT) should be discussed from the first presentation of the disease, and SU levels should be maintained at less than 6 mg/dl (360 µmol/l), or less than 5 mg/dl (300 µmol/l) in patients with severe gout. Allopurinol is recommended as first -line ULT with dose adjustment according to renal function. If the SU target cannot be achieved with allopurinol,

show abstract

“…Notably, measures of disease activity including serum urate acid (SUA) levels, frequency of flares, and the presence of tophi have all been linked to higher costs 2,3 . Evidence demonstrates that health-related quality of life (HRQOL) is lower in the gout population when compared with the healthy population, largely attributed to the painful flares and physical disability associated with the disease 2,4 . The global burden of gout is rising; disability-adjusted life-years increased from 76,000 in 1990 to 114,000 in 2010 1 .…”

Section: The Economic Value Of Genetic Testing For Tolerance Of Allopmentioning

confidence: 99%